(CercleFinance.com) – Ipsen announces the signing of an exclusive global collaboration agreement with Skyhawk Therapeutics, aimed at the discovery and development of new small molecules capable of modulating RNA splicing in rare neurological diseases.
This agreement gives Ipsen the option to acquire an exclusive license for the worldwide rights to develop validated drug candidates. Once the development candidate is selected, he will be responsible for all activities concerning him.
Skyhawk is eligible for an upfront payment for the research collaboration, payments contingent on exercise of option and regulatory and commercial milestones, totaling up to $1.8 billion, as well as potential royalties.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
